Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{205780,
        author = {Abhay Yadav and Ved Prakash Tiwari and Ashish Srivastava and Pramod Kumar Mishra and Monu Kumar Kashyap and Karuna S Shukla},
        title = {Eudragit S100-coated PLGA nanoparticles for colon-targeted prednisolone delivery in ulcerative colitis: formulation optimization and in vitro evaluation},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {7798-7807},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=205780},
        abstract = {— Ulcerative colitis is a relapsing inflammatory disease of the colon in which local corticosteroid exposure is desirable, whereas unnecessary systemic exposure can increase adverse effects. Prednisolone is an effective glucocorticoid; however, conventional oral delivery may release drug before the formulation reaches the distal intestine. The present work developed pH-responsive colon-targeted prednisolone nanoparticles using a biodegradable PLGA core, PVA as stabilizer and Eudragit S100 as an enteric coating polymer. Prednisolone-loaded nanoparticles were prepared by solvent displacement and optimized using a three-factor Box-Behnken design. The effects of PLGA amount, PVA concentration and Eudragit S100 amount were assessed on particle size, PDI, zeta potential, entrapment efficiency, percentage yield and 24 h cumulative release. The optimized coated nanoparticles contained PLGA 120 mg, PVA 0.6% w/v and Eudragit S100 75 mg and showed particle size of 214.6 ± 6.8 nm, PDI of 0.214 ± 0.018, zeta potential of -31.8 ± 1.6 mV, entrapment efficiency of 82.4 ± 2.1%, drug content of 96.8 ± 2.7% and 24 h release of 76.9 ± 3.1%. Sequential pH release demonstrated restricted acidic release followed by progressive drug liberation at intestinal/colonic pH. Release kinetics were most consistent with Higuchi and Korsmeyer-Peppas models, supporting diffusion-dominant release with polymer relaxation contribution. Mucin binding reached 79.4 ± 3.8% at 60 min, hemolysis remained below 5% up to 400 ug/mL and Caco-2 viability remained above 75% up to 200 ug/mL. These findings support Eudragit S100-coated PLGA nanoparticles as a promising in vitro platform for colon-targeted prednisolone delivery.},
        keywords = {prednisolone; ulcerative colitis; colon-targeted drug delivery; PLGA nanoparticles; Eudragit S100; Box-Behnken design; pH-responsive release; mucin binding},
        month = {June},
        }